Results 141 to 150 of about 5,674 (178)

Comparative analysis of phytocompounds and repurposed drugs against dengue virus serotypes employing an in silico study. [PDF]

Sci Rep
Vats P, Rolta R, Salaria D, Sharma I, Verma A, Fadare OA, Verma M.   +6 more
europepmc   +1 more source

The Genotypes/Subtypes and Antiviral Drug Resistance of the Hepatitis C Virus from Patients in a Tertiary Care Hospital in Nepal. [PDF]

Viruses
Kattel HP, Sharma S, Alfsnes K, Pettersson JH, Pathak R, Engebretsen SB, Rijal KR, Ghimire P, Andreassen ÅK, Banjara MR.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Daclatasvir

Annals of Pharmacotherapy, 2016
Michael Smith, Rima Mohammad
exaly   +2 more sources

Isothermal titration calorimetry and molecular modeling study of the complex formation of daclatasvir by γ-cyclodextrin and trimethyl-β-cyclodextrin

Carbohydrate Polymers, 2023
International audienceThe complex formation between daclatasvir and γ-CD or heptakis(2,3,6-tri-O-methyl)-β-CD (TM-β-CD) was studied by isothermal titration calorimetry and molecular modeling.
David Landy, Antonio Salgado, Sulaiman Krait   +2 more
exaly   +2 more sources

A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019

New Microbes and New Infections, 2021
Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae ...
R. Dowran, Shabani, M., Sadegh Ehdaei, B., F. Fathi, Fathi, F., Dowran, R., B. Sadegh Ehdaei, M. Shabani   +7 more
exaly   +2 more sources

Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients [PDF]

Journal of Hepatology, 2017
International audienceBackground & aims - We report the first real-life results of the sofosbuvir+daclatasvir combination in hepatitis C virus (HCV) genotype 1 infected patients.
Hélène Fontaine, Isabelle Rosa, Patrick Marcellin   +2 more
exaly   +2 more sources

The safety of daclatasvir for the treatment of hepatitis C

Expert Opinion on Drug Safety, 2015
INTRODUCTION: The direct acting antiviral daclatasvir is an NS5A replication inhibitor active against the entire range of hepatitis C virus genotypes. It is a key step in establishing the goal of an all-oral, ribavirin-free, pan-genotypic regimen against
Gordon, Stuart C, Jafri, Syed-Mohammed
exaly   +2 more sources

Asunaprevir/daclatasvir

Reactions Weekly, 2016
  +11 more sources

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme

Liver International, 2017
International audienceBACKGROUND & AIMS:Optimally effective treatment for hepatitis C virus genotype 3 (GT3) is urgently needed, particularly in advanced liver disease. Daclatasvir plus sofosbuvir was efficacious in phase 3 studies.
Hélène Fontaine, Isabelle Rosa, Eric Nguyen-Khac   +2 more
exaly   +2 more sources